Sanford C. Bernstein Boosts Insulet (NASDAQ:PODD) Price Target to $410.00

Insulet (NASDAQ:PODD) had its price target hoisted by stock analysts at Sanford C. Bernstein from $400.00 to $410.00 in a report released on Friday,MarketScreener reports. Sanford C. Bernstein’s target price points to a potential upside of 28.20% from the stock’s previous close.

PODD has been the subject of a number of other reports. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, October 14th. Stifel Nicolaus assumed coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price on the stock. Canaccord Genuity Group raised their target price on Insulet from $399.00 to $428.00 and gave the company a “buy” rating in a research report on Friday. Raymond James Financial boosted their price target on shares of Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Morgan Stanley reissued an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $370.76.

Insulet Trading Down 1.1%

PODD opened at $319.82 on Friday. Insulet has a fifty-two week low of $230.05 and a fifty-two week high of $353.50. The firm has a market capitalization of $22.51 billion, a PE ratio of 97.21, a P/E/G ratio of 2.64 and a beta of 1.39. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company’s 50-day moving average is $325.06 and its 200 day moving average is $309.40.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million during the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company’s quarterly revenue was up 29.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts predict that Insulet will post 3.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president directly owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PODD. Larson Financial Group LLC raised its position in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT bought a new position in shares of Insulet during the first quarter valued at about $26,000. SouthState Corp increased its holdings in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after buying an additional 76 shares during the period. True Wealth Design LLC increased its holdings in shares of Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period. Finally, Kozak & Associates Inc. bought a new stake in shares of Insulet in the 2nd quarter valued at about $32,000.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.